Utilization and costs of cardiovascular disease medications in dialysis patients in medicare part D

American Journal of Kidney Diseases

Volumn 59, Issue 5, 2012, Pages 670-681

  Frankenfield, Diane L ^a   Weinhandl, Eric D ^b   Powers, Christopher A ^a   Howell, Benjamin L ^a   Herzog, Charles A ^b,c   St Peter, Wendy L ^b,d  

^a CENTERS FOR MEDICARE AND MEDICAID SERVICES   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

cardiovascular medications; cost; Dialysis; low income subsidy; Medicare Part D; utilization

Indexed keywords

ALISKIREN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIGOXIN; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DOXAZOSIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; MINOXIDIL; POTASSIUM SPARING DIURETIC AGENT; PRAZOSIN; TERAZOSIN; THIAZIDE DIURETIC AGENT; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DEMOGRAPHY; DRUG CONTRAINDICATION; DRUG COST; DRUG UTILIZATION; FEMALE; FOLLOW UP; GEOGRAPHY; HEART ATRIUM FIBRILLATION; HEMODIALYSIS PATIENT; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICARE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESCRIPTION; RETROSPECTIVE STUDY; TRANSIENT ISCHEMIC ATTACK; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COST OF ILLNESS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; KIDNEY DISEASES; MALE; MEDICARE PART D; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84859801261     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2011.10.047     Document Type: Article

References (72)

1. US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Am J Kidney Dis. 2011;57(1)(suppl 1):e1-e526.
2. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(suppl 12):S16-S23.
3. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis. 2005;45(suppl 3):S1-153.
4. Madore F. Uremia-related metabolic cardiac risk factors in chronic kidney disease. Semin Dial. 2003;16(2):148-156. (Pubitemid 37356827)
5. Foley RN. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial. 2003;16(2):111-117. (Pubitemid 37356823)
6. Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002;13(7):1918-1927. (Pubitemid 34700618)
7. Gupta R, Birnbaum Y, Uretsky BF. The renal patient with coronary artery disease: current concepts and dilemmas. J Am Coll Cardiol. 2004;44(7):1343-1353. (Pubitemid 39303931)
8. Haim M, Shotan A, Boyko V, et al. Effect of beta-blocker therapy in patients with coronary artery disease in New York Heart Association classes II and III. The Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol. 1998;81(12):1455-1460. (Pubitemid 28283828)
9. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349-1355. (Pubitemid 26152713)
10. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-153.
11. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360(9335):752-760. (Pubitemid 35247704)
12. Cohn JN, Tognoni G.Arandomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-1675. (Pubitemid 33126822)
13. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273(18):1450-1456.
14. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-1158. (Pubitemid 36398384)
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
16. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363-2372. (Pubitemid 43947981)
17. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107(12):1692-1711. (Pubitemid 36397341)
18. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492-501. (Pubitemid 29482392)
19. Ishani A, Herzog CA, Collins AJ, Foley RN. Cardiac medications and their association with cardiovascular events in incident dialysis patients: cause or effect? Kidney Int. 2004;65(3):1017-1025. (Pubitemid 38251078)
20. Wetmore JB, Shireman TI. TheABCs of cardioprotection in dialysis patients: a systematic review. Am J Kidney Dis. 2009;53(3):457-466.
21. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41(9):1438-1444. (Pubitemid 36543357)
22. Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006;70(7):1318-1324. (Pubitemid 44435184)
23. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-1407.
24. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-248. (Pubitemid 41058323)
25. Tai DJ, Lim TW, James MT, Manns BJ, Tonelli M, Hemmelgarn BR. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis. Clin J Am Soc Nephrol. 2010;5(4):623-630.
26. Akbari A, Knoll G, Ferguson D, McCormick B, Davis A, Biyani M.Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta-analysis of randomized controlled trials. Perit Dial Int. 2009;29(5):554-561.
27. Cice G, Di BA, D'Isa S, et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol. 2010;56(21):1701-1708.
28. Suzuki H. Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis. Ther Adv Cardiovasc Dis. 2009;3(5):397-405.
29. Suzuki H, Kanno Y, Sugahara S, et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis. 2008;52(3):501-506.
30. Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - a randomized study. Nephrol Dial Transplant. 2006;21(9):2507-2512. (Pubitemid 44644524)
31. Winkelmayer WC, Charytan DM, Levin R, Avorn J. Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction. Am J Kidney Dis. 2006;47(2):301-308. (Pubitemid 43121333)
32. McCullough PA, Sandberg KR, Yee J, Hudson MP. Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. J Renin Angiotensin Aldosterone Syst. 2002;393):188-191.
33. Efrati S, Zaidenstein R, Dishy V, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis. 2002;40(5):1023-1029. (Pubitemid 35265483)
34. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;103(7):987-992. (Pubitemid 32183805)
35. Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL. Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med. 2004;164(22):2465-2471. (Pubitemid 39628074)
36. Tepel M, GietMV, Park A, ZidekW. Association of calcium channel blockers and mortality in haemodialysis patients. Clin Sci (Lond). 2002;103(5):511-515. (Pubitemid 35305636)
37. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int. 2002;61(6):2157-2164. (Pubitemid 34539333)
38. Goldfarb-Rumyantzev AS, Habib AN, Baird BC, Barenbaum LL, Cheung AK. The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. Am J Kidney Dis. 2007;50(5):791-802. (Pubitemid 47588556)
39. Mason NA, Bailie GR, Satayathum S, et al. HMGcoenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis. 2005;45(1):119-126. (Pubitemid 40038052)
40. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61(1):297-304. (Pubitemid 34075157)
41. Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol. 2009;20(4):705-711.
42. Holden RM, Harman GJ, Wang M, Holland D, Day AG. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(1):105-110.
43. Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis. 2007;50(3):433-440. (Pubitemid 47285456)
44. Vazquez E, Sanchez-Perales C, Garcia-Cortes MJ, et al. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants? Int J Cardiol. 2003;87(2-3):135-139. (Pubitemid 36135967)
45. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol. 2009;20(4):872-881.
46. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20(10):2223-2233.
47. Wiesholzer M, Harm F, Tomasec G, Barbieri G, Putz D, Balcke P. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol. 2001;21(1):35-39. (Pubitemid 32238611)
48. Abbott KC, Trespalacios FC, Taylor AJ, Agodoa LY. Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol. 2003;4:1.
49. Lopes AA, Bragg-Gresham JL, Ramirez SP, et al. Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS. Nephrol Dial Transplant. 2009;24(9):2809-2816.
50. Sood MM, Battistella M, Lok CE. Patterns of cardioprotective medication prescription in incident hemodialysis patients. Int Urol Nephrol. 2009;41(4):1021-1027.
51. Ranchord AM, Harding SA, Pidgeon G. Medications for the secondary prevention of ischaemic heart disease and heart failure are underutilized in dialysis patients. Intern Med J. 2008;38(5):361-364. (Pubitemid 351519491)
52. Roy P, Bouchard J, Amyot R, Madore F. Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients. Am J Kidney Dis. 2006;48(4):645-651. (Pubitemid 44402833)
53. Miller LM, Hopman WM, Garland JS, Yeates KE, Pilkey RM. Cardioprotective medication use in hemodialysis patients. Can J Cardiol. 2006;22(9):755-760. (Pubitemid 44227472)
54. Andreucci VE, Fissell RB, Bragg-Gresham JL, et al. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis. 2004;44(5)(suppl 2):61-67.
55. Rahman M, Griffin V. Patterns of antihypertensive medication use in hemodialysis patients. Am J Health Syst Pharm. 2004;61(14):1473-1478. (Pubitemid 39481419)
56. Fox CS, Longenecker JC, Powe NR, et al. Undertreatment of hyperlipidemia in a cohort of United States kidney dialysis patients. Clin Nephrol. 2004;61(5):299-307. (Pubitemid 38579015)
57. Manley HJ, Garvin CG, Drayer DK, et al. Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant. 2004;19(7):1842-1848. (Pubitemid 38961397)
58. Chow FY, Polkinghorne KR, Chadban SJ, Atkins RC, Kerr PG. Cardiovascular risk in dialysis patients: a comparison of risk factors and cardioprotective therapy between 1996 and 2001. Nephrology (Carlton). 2003;8(4):177-183. (Pubitemid 36995087)
59. Tozawa M, Iseki K, Iseki C, et al. Analysis of drug prescription in chronic haemodialysis patients. Nephrol Dial Transplant. 2002;17(10):1819-1824. (Pubitemid 35174296)
60. Trespalacios FC, Taylor AJ, Agodoa LY, Abbott KC. Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int. 2002;62(5):1799-1805. (Pubitemid 35286289)
61. Manley HJ, Bailie GR, Grabe DW. Comparing medication use in two hemodialysis units against national dialysis databases. Am J Health Syst Pharm. 2000;57(9):902-906. (Pubitemid 30253802)
62. United States Congress. Medicare Prescription Drug Improvement and Modernization Act of 2003 Public Law 108-173. 2003. http://www.gpo.gov/fdsys/ pkg/PLAW-108publ173/pdf/PLAW-108publ173.pdf. Accessed June 10, 2011.
63. Knoll GA, Sahgal A, Nair RC, Graham J, van WC, Burns KD. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med. 2002;112(2):110-114. (Pubitemid 34142541)
64. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61(5):1887-1893. (Pubitemid 34437945)
65. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63(3):793-808. (Pubitemid 36315558)
66. Loghman-Adham M. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care. 2003;9(2):155-171. (Pubitemid 36292404)
67. Schmid H, Hartmann B, Schiffl H. Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res. 2009;14(5):185-190.
68. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089-1096.
69. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31(3):213-224.
70. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41(suppl 3):S1-S92.
71. National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis. 2004;43(suppl 1):S1-S290.
72. National Kidney Foundation. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(suppl 2):S1-S180.